1932

Abstract

I was honored to be asked by the Editorial Committee of the to write an autobiographical account of my life in science and in genetics in particular. The field has moved from mapping Mendelian disorders 40 years ago to the delivery of effective therapies for some monogenic disorders today. My 40-year journey from diagnosis to therapy for Duchenne muscular dystrophy has depended on collaborations among basic scientists, clinicians, medical charities, genetic counselors, biotech companies, and affected families. The future of human genetics looks even more exciting, with techniques such as single-cell sequencing and somatic cell CRISPR editing opening up opportunities for precision medicine and accelerating progress.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-genom-112019-083518
2020-08-31
2024-04-16
Loading full text...

Full text loading...

/deliver/fulltext/genom/21/1/annurev-genom-112019-083518.html?itemId=/content/journals/10.1146/annurev-genom-112019-083518&mimeType=html&fmt=ahah

Literature Cited

  1. 1. 
    Bakker E, Goor N, Wrogemann K, Kunkel LM, Fenton WA et al. 1985. Prenatal diagnosis and carrier detection of Duchenne muscular dystrophy with closely linked RFLPs. Lancet 325:655–58
    [Google Scholar]
  2. 2. 
    Botstein D, White RL, Skolnick M, Davis RW 1980. Construction of a genetic linkage map in man using restriction fragment length polymorphisms. Am. J. Hum. Genet. 32:314–31
    [Google Scholar]
  3. 3. 
    Cohn RD, Campbell KP. 2000. Molecular basis of muscular dystrophies. Muscle Nerve 23:1456–71
    [Google Scholar]
  4. 4. 
    Collins FS, Riordan JR, Tsui LC 1990. The cystic fibrosis gene: isolation and significance. Hosp. Pract. 25:47–57
    [Google Scholar]
  5. 5. 
    Crudele JM, Chamberlain JS. 2019. AAV-based gene therapies for the muscular dystrophies. Hum. Mol. Genet. 28:R102–7
    [Google Scholar]
  6. 6. 
    Davies KE, Young BD, Elles RG, Hill ME, Williamson R 1981. Cloning of a representative genomic library of the human X chromosome after sorting by flow cytometry. Nature 293:374–76
    [Google Scholar]
  7. 7. 
    Demirci S, Leonard A, Haro-Mora JJ, Uchida N, Tisdale JF 2019. CRISPR/Cas9 for sickle cell disease: applications, future possibilities, and challenges. Adv. Exp. Med. Biol. 1144:37–52
    [Google Scholar]
  8. 8. 
    Drayna D, Davies KE, Hartley D, Mandel JL, Camerino G et al. 1984. Genetic mapping of the human X chromosome by using restriction fragment length polymorphisms. PNAS 81:2836–39
    [Google Scholar]
  9. 9. 
    Duan DS. 2018. Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy. Mol. Ther. 26:2337–56
    [Google Scholar]
  10. 10. 
    Emery AEH. 2002. The muscular dystrophies. Lancet 359:687–95
    [Google Scholar]
  11. 11. 
    England SB, Nicholson LVB, Johnson MA, Forrest SM, Love DR et al. 1990. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 343:180–82
    [Google Scholar]
  12. 12. 
    Guiraud S, Aartsma-Rus A, Vieira NM, Davies KE, van Ommen G-JB, Kunkel LM 2015. The pathogenesis and therapy of muscular dystrophies. Annu. Rev. Genom. Hum. Genet. 16:281–308
    [Google Scholar]
  13. 13. 
    Guiraud S, Roblin D, Kay DE 2018. The potential of utrophin modulators for the treatment of Duchenne muscular dystrophy. Expert Opin. Orphan Drugs 6:179–92
    [Google Scholar]
  14. 14. 
    Gusella JF. 1984. Genetic linkage of the Huntington's disease gene to a DNA marker. Can. J. Neurol. Sci. 11:421–25
    [Google Scholar]
  15. 15. 
    Kan YW, Dozy AM. 1978. Antenatal diagnosis of sickle-cell anæmia by D.N.A. analysis of amniotic-fluid cells. Lancet 312:910–12
    [Google Scholar]
  16. 16. 
    Kingston HM, Harper PS. 1983. Genetic linkage between Becker muscular dystrophy and polymorphic DNA probes on the short arm of the X chromosome. J. Med. Genet. 20:454–58
    [Google Scholar]
  17. 17. 
    Lefebvre S, Burglin L, Reboullet S, Clermont O, Burlet P et al. 1995. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80:155–65
    [Google Scholar]
  18. 18. 
    Love DR, Hill DF, Dickson G, Spurr NK, Byth BC et al. 1989. An autosomal transcript in skeletal muscle with homology to dystrophin. Nature 339:55–58
    [Google Scholar]
  19. 19. 
    Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac L et al. 2016. Gene therapy for spinal muscular atrophy type 1 shows potential to improve survival and motor functional outcomes. Mol. Ther. 24:Suppl. 1S190
    [Google Scholar]
  20. 20. 
    Murray JM, Davies KE, Harper PS, Meredith L, Mueller CR, Williamson R 1982. Linkage relationship of a cloned DNA sequence on the short arm of the X chromosome to Duchenne muscular dystrophy. Nature 300:69–71
    [Google Scholar]
  21. 21. 
    Talbot K, Tizzano EF. 2017. The clinical landscape for SMA in a new therapeutic era. Gene Ther 24:529–33
    [Google Scholar]
  22. 22. 
    Verhaart IEC, Aartsma-Rus A. 2019. Therapeutic developments for Duchenne muscular dystrophy. Nat. Rev. Neurol. 15:373–86
    [Google Scholar]
  23. 23. 
    Wilkinson IVL, Perkins KJ, Dugdale H, Moir L, Vuorinen A et al. 2020. Chemical proteomics and phenotypic profiling identifies the aryl hydrocarbon receptor as a molecular target of the utrophin modulator ezutromid. Angew. Chem. Int. Ed. 59:2420–28
    [Google Scholar]
  24. 24. 
    Willard HF, Schmeckpeper BJ, Smith KD, Goss SJ 1982. Regional localization of an X-specific DNA restriction fragment on the human X chromosome. Cytogenet. Cell Genet. 32:328 Abstr
    [Google Scholar]
/content/journals/10.1146/annurev-genom-112019-083518
Loading
/content/journals/10.1146/annurev-genom-112019-083518
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error